Novo’s late-stage pipeline is set to balloon with three new pivotal trials planned; data due in Alzheimer’s could add a whole new storyline.
The Swiss group moves to start a further trial of prasinezumab, but this will not be phase III.
As antibody tests pile up, Oxford Immunotec is working on an assay to detect T cell responses to the coronavirus.
Pfizer/Biontech’s preprint might prove academic as investors look to pivotal study designs and readouts.
Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.